Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
Acelyrin宣佈其Lonigutamab甲狀腺眼病1/2期臨床試驗的數據將在歐洲眼科整形和重建手術學會的年會上分享
Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
Acelyrin宣佈，將在歐洲眼科整形和重建外科學會年會上分享其治療甲狀腺眼病的Lonigutamab的1/2期臨床試驗的數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間